GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-20 |
2024-03 |
0 |
N/A |
N/A |
N/A |
2024-04-05 |
2023-12 |
0 |
N/A |
N/A |
N/A |
2023-11-14 |
2023-09 |
0 |
-3.64 |
N/A |
N/A |
2023-08-14 |
2023-06 |
0 |
-19.52 |
N/A |
N/A |
2023-05-15 |
2023-03 |
0 |
N/A |
N/A |
N/A |
Date |
Name |
Relation |
Quantity |
Description |
2023-04-20 |
AGRO ALBERT |
Officer |
172.19K |
Stock Award(Grant) |
2021-02-11 |
BAKER DAVID CHARLES |
Chief Executive Officer |
8.84K |
Purchase |
2023-04-20 |
CHATURVEDI VIPIN |
Officer |
172.19K |
Stock Award(Grant) |
2023-04-20 |
HERTZ WALTER MARC |
Chief Executive Officer |
385.51K |
Stock Award(Grant) |
2021-06-03 |
KELLY LEANNE M |
Chief Financial Officer |
6.25K |
Purchase |
2021-05-25 |
PAYNE JOSEPH E |
Director |
861.25K |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Altium Capital Management, LP |
1.18M |
5.01M |
39.89% |
2023-06-29 |
Geode Capital Management, LLC |
14.88K |
63.23K |
0.50% |
2023-06-29 |
Tower Research Capital LLC (TRC) |
2.58K |
10.95K |
0.09% |
2023-06-29 |
UBS Group AG |
899.00 |
3.82K |
0.03% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-05-30 |
Fidelity Extended Market Index Fund |
275.00 |
1.64K |
0.01% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
318.00 |
1.90K |
0.01% |
2023-06-29 |
Vanguard Extended Market Index Fund |
427.00 |
1.81K |
0.01% |
Dividend |
Date |
0.511 |
2019-12-19 |
0.27 |
2019-09-19 |
0.373 |
2019-06-20 |
0.346 |
2019-03-21 |
0.409 |
2018-12-20 |
0.221 |
2018-09-20 |
Split |
Date |
1 : 7 |
2024-01-30 |
1 : 30 |
2023-04-24 |